Skip to main content
. 2019 Oct 15;191(41):E1128–E1135. doi: 10.1503/cmaj.190047

Figure 4:

Figure 4:

Summary of the overall approach to glucose-lowering medications in type 2 diabetes as recommended by the 2018 consensus report of the American Diabetes Association and European Association for the Study of Diabetes.34 Note: ASCVD = atherosclerotic cardiovascular disease, CKD = chronic kidney disease, CVD = cardiovascular disease, eGFR = estimated glomerular filtration rate, GLP-1 = glucagon-like peptide-1, HbA1c = glycated hemoglobin, SGLT2 = sodium-glucose cotransporter-2.